• Aucun résultat trouvé

HER2-positive

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

... with HER2-positive breast cancer were recruited through the French PHARE/ SIGNAL trial 19,20 ...with HER2 overexpression and had provided signed informed ...clinical HER2 status was assessed ...

10

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

... of HER2 concentrations (0 to 1694 amol/µg) in breast cancer samples, all considered as HER2-positive by ...as positive with gold standard IHC and/or FISH but had low amount of HER2 ...

17

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma

... the HER2-negative (or trastuzu- mab (TZM) insensitive) subtypes (phase I [1], phases II [2, 3], phases III ...the HER2-positive subtype (25 % vs 11 % in the whole population) ...on ...

11

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

... analysis does not demonstrate signi ficant impact of per- tuzumab on mortality. OS data are immature at this point. Only 42.5% of the 640 deaths required for the final analysis have occurred. Therefore, patient follow-up ...

12

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells

... Published: 7 November 2013 doi:10.1186/2051-1426-1-S1-P176 Cite this article as: Valsesia-Wittmann et al.: Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive ...

2

Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment.

Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment.

... Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment. Onesti CE 1,2,3 ...

1

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

... Overall, approximately 7–27% of all new breast cancers in high-income countries are treated with neoadjuvant chemotherapy (NAC) treatment [2]. Pre-operative treatment allows rapid assessment of drug efficacy, and the ...

15

What do we learn from HER2-positive breast cancer genomic profiles?

What do we learn from HER2-positive breast cancer genomic profiles?

... further work in order to determine the lines along which we will delineate the different subsets of HER2-positive breast cancers. It will be interesting, in particular, to see whether it is possible to ...

7

Anti-HER2 vaccines: new prospects for breast cancer therapy.

Anti-HER2 vaccines: new prospects for breast cancer therapy.

... strongly HER2-positive cancers (IHC: 3+), the combination of trastuzumab followed by vaccination with the E75 peptide seemed safe and immunologically beneficial ...anti- HER2 peptide-based vaccine ...

44

The Dilemma of HER2 Double-equivocal Breast Carcinomas

The Dilemma of HER2 Double-equivocal Breast Carcinomas

... double-equivocal HER2 status demonstrates the possibility of biologically and prognostically stratifying these carcinomas, a feature that may be instrumental to support treatment decision- ...with ...

11

Le profil hormonal, Her2 et prolifratif des carcinomes mammaires infiltrants, avec approche de classification molculaire

Le profil hormonal, Her2 et prolifratif des carcinomes mammaires infiltrants, avec approche de classification molculaire

... node positive tumors were observed in ...receptor positive (74,6%) and 27% were HER2 ...Negative, HER2 subtype tend to spread more aggressively and are associated with poorer ...

146

Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice

Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice

... Mouse model We developed a mouse model bearing a different tumour (i.e. one HER2-positive and one HER2-negative tumour) at each flank. This approach provides an ideal negative control and enables ...

8

[Anti-EGFR and anti-HER2 monoclonal antibodies against pancreatic carcinomas]

[Anti-EGFR and anti-HER2 monoclonal antibodies against pancreatic carcinomas]

... ou HER2 ont été approuvés par la FDA et l’EMEA (European Agency for the Evaluation of Medicinal Products) et sont utilisés quotidiennement en clinique, comme le trastuzumab, dirigé contre HER2, pour le ...

5

Isolation and characterization of camelid single-domain antibodies against HER2

Isolation and characterization of camelid single-domain antibodies against HER2

... he DNA sequences encoding the six V H Hs were cloned into the pSJF2H expression vector [ 8 ]. C-termi- nally c-Myc- and His 6 -tagged V H Hs were expressed in 200 mL overnight cultures of E. coli TG1 under IPTG induction ...

6

Le CpG et le poly(I:C) agissent en synergie avec le trastuzumab contre le cancer du sein HER2+

Le CpG et le poly(I:C) agissent en synergie avec le trastuzumab contre le cancer du sein HER2+

... xxxi Chapitre 3 : Matériels et méthodes 3.1 Traitement des tumeurs transplantées et immunité mémoire Les modèles murins sont particulièrement intéressants de par leur côté pratique (faible coût, reproduction rapide, ...

97

Traitement néoadjuvant du cancer du sein HER2-positif : à propos de l'étude EORTC LAPATAX

Traitement néoadjuvant du cancer du sein HER2-positif : à propos de l'étude EORTC LAPATAX

... tumeurs HER2-positives ayant reçu une chimiothérapie néoadjuvante contenant des taxanes et un traitement par trastuzumab non en RCH entre un bras poursuite du trastuzumab pour une durée d’un an (bras standard) et ...

151

Non positive SVM

Non positive SVM

... It has been shown ([13]) that learning with non positive kernel is actually solving the learning problem in a Krein space instead of a Hilbert space. It has also been shown that in this situation, the learning ...

16

Une théorie positive de l'information et des choix

Une théorie positive de l'information et des choix

... Nous procéderons par étapes en résumant d'abord tous les facteurs qui déterminent le coût de la recherche personnelle , l'écart subjectif de competence , et la difficulté du choix pers[r] ...

46

Positive multistate protein design

Positive multistate protein design

... Solving positive min -MSD with iCFN Recently, a guaranteed CFN-based algorithm for both positive and negative min-MSD was intro- duced as the iCFN method ( Karimi and Shen , 2018 ...

12

Discrimination positive et mobilité scolaire

Discrimination positive et mobilité scolaire

... 77 sorties vers l’enseignement spécialisé, proportionnellement plus fréquentes dans les écoles en discrimination positive que dans les autres. Si ce schéma se distingue de celui jusqu’ici mieux connu de ...

153

Show all 702 documents...

Sujets connexes